

Post Test, Evaluation, and Credit Application

From Pre-Emptive to Salvage Antifungal Therapy: Achieving Successful Outcomes

On-demand Webinar

(Release date: 4/20/2009 Expiration date: 4/21/2010)

Your professional title: ☐ Physician ☐ Pharmacist Other _____

Your practice setting: ☐ Teaching hospital ☐ Community hospital ☐ LTAC
Other _____

INSTRUCTIONS for CREDIT

1. Review the On-demand Webinar in its entirety.
2. Print and complete the Post Test, Evaluation, and Credit Application form.
3. Mail the completed Post Test, Evaluation, and Credit Application form to
Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807
OR
Fax to (908) 235-4222.

Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application form.

Your evaluation and suggestions will help improve the quality of future continuing education activities. Please answer the following general questions, provide written comments, and evaluate the individual faculty. Additional space for your comments and suggestions is available. Thank you for your cooperation.

POST TEST (Please check the most appropriate answer)

1. According to the 2009 IDSA guidelines, which of the following is not a preferred first-line agent for the treatment of invasive candidiasis in neutropenic patients?

- ☐ Amphotericin B deoxycholate
- ☐ Amphotericin B lipid complex
- ☐ Voriconazole
- ☐ Caspofungin

2. Which organism exhibits intrinsic resistance to amphotericin B?

- ☐ *Candida albicans*
- ☐ *Cryptococcus neoformans*
- ☐ *Aspergillus fumigatus*
- ☐ *Aspergillus terreus*

3. Which organism exhibits intrinsic resistance to the echinocandins?

- ☐ *Candida albicans*
- ☐ *Candida glabrata*
- ☐ *Candida tropicalis*
- ☐ *Cryptococcus neoformans*

POST TEST (Please check the most appropriate answer)
<p>4. Zygomycosis superinfections have been associated with the use of which antifungal agent?</p> <p><input type="checkbox"/> Fluconazole</p> <p><input type="checkbox"/> Voriconazole</p> <p><input type="checkbox"/> Caspofungin</p> <p><input type="checkbox"/> Micafungin</p>
<p>5. According to the 2009 IDSA guidelines on the management of invasive candidiasis, a patient who has received azole prophylaxis should not be given . . .</p> <p><input type="checkbox"/> Voriconazole</p> <p><input type="checkbox"/> Caspofungin</p> <p><input type="checkbox"/> Amphotericin B lipid complex</p> <p><input type="checkbox"/> Liposomal amphotericin B</p>
<p>6. Which diagnostic technique is not considered to be a part of pre-emptive approach for patient management?</p> <p><input type="checkbox"/> Cell culture</p> <p><input type="checkbox"/> β-D-glucan assay</p> <p><input type="checkbox"/> CT scan</p> <p><input type="checkbox"/> Galactomannan assay</p>
<p>7. Which of the following is not a risk factor for candidiasis in ICU patients?</p> <p><input type="checkbox"/> Antifungal prophylaxis</p> <p><input type="checkbox"/> Presence of central venous catheter</p> <p><input type="checkbox"/> Total parenteral nutrition</p> <p><input type="checkbox"/> Use of steroids</p>
<p>8. For patients with candidemia who fail treatment, all of the following should be considered EXCEPT:</p> <p><input type="checkbox"/> Catheter removal</p> <p><input type="checkbox"/> Combination therapy</p> <p><input type="checkbox"/> Changing antifungal class for retreatment</p> <p><input type="checkbox"/> Identifying <i>Candida</i> species to predict susceptibility</p>
<p>9. Which of the following agents is most effective in killing <i>Candida</i> biofilms?</p> <p><input type="checkbox"/> Fluconazole</p> <p><input type="checkbox"/> Itraconazole</p> <p><input type="checkbox"/> Caspofungin</p> <p><input type="checkbox"/> Amphotericin B deoxycholate</p>
<p>10. The best clinical evidence supporting combination therapy is for treatment of infections caused by . . .</p> <p><input type="checkbox"/> <i>Candida</i></p> <p><input type="checkbox"/> <i>Cryptococcus</i></p> <p><input type="checkbox"/> <i>Aspergillus</i></p> <p><input type="checkbox"/> Zygomycetes</p>

LEARNING OBJECTIVES: Were the learning objectives met?	Yes	Somewhat	No
Distinguish between the advantages of a pre-emptive strategy and empiric treatment when managing patients with IFIs			
Identify the causes of treatment failure and recognize options for salvage therapy			
If you answered 'No' to any objective, please explain.			

FACULTY	Excellent	Good	Fair	Poor
Elizabeth S. Dodds Ashley, PharmD, MHS, BCPS				
Teaching ability				
Knowledge and expertise in the subject				
John R. Perfect, MD				
Teaching ability				
Knowledge and expertise in the subject				
OVERALL EVALUATION		Yes	Somewhat	No
1. This activity met my expectations.				
2. The content was relevant to my practice.				
3. This activity was fair and balanced.				
4. This activity was without commercial bias.				
If you answered "No" to 3 or 4, please explain.				
LEARNING FORMAT		Yes	Somewhat	No
1. The course format enhanced achievement of learning objectives.				
2. The format was easy to follow and understand.				
ACTIVITY MANAGEMENT		Yes	Somewhat	No
1. On-demand Webinar was easy to access.				
2. On-demand Webinar format was conducive to learning.				
PRACTICE APPLICATION				
1. What aspects of this activity were most relevant to your practice?				
2. Please list two causes of antifungal failure that you learned in this activity.				
3. Do you intend to make changes to your practice based on participation in this activity? If yes, please specify.				
4. What aspects of IFIs do you need to learn more about to improve your practice performance?				
DO YOU HAVE (1) ANY SUGGESTIONS FOR IMPROVING THIS ACTIVITY or (2) ANY ADDITIONAL COMMENTS?				

POST ACTIVITY SURVEY (Please check all that apply)

Center for Independent Healthcare Education is dedicated to promoting a spirit of lifelong learning and continuous professional development. To that end, we are interested in understanding your specific barriers and challenges. Please take a few moments to complete this Post Activity Survey. Please note that your individual responses will be kept confidential.

Are you familiar with the guidelines recently released by the Infectious Diseases Society of America on the management of aspergillosis and candidiasis?

- ☐ Yes, I have read them
- ☐ Yes, but I have not read both of them carefully
- ☐ No, I am not aware of them

What are the greatest challenges you face when managing patients with IFIs?

- ☐ Choosing an appropriate antifungal agent
- ☐ Deciding on the optimal dose of an antifungal agent
- ☐ Identification of the pathogen in a timely manner
- ☐ Obtaining susceptibility results
- ☐ Minimizing drug-drug interactions
- ☐ Minimizing adverse events
- ☐ Deciding on the appropriate length of therapy
- ☐ Other (please explain) _____

Do you consider yourself well-equipped in selecting appropriate empiric antifungal therapy for patients with IFIs?

- ☐ I have knowledge of guidelines and recent clinical research and know what to do
- ☐ I have knowledge of guidelines and recent clinical research but do not know how to implement this knowledge in clinical practice
- ☐ I need more information on the guidelines and clinical research in order to implement this knowledge in clinical practice
- ☐ Other (please specify) _____

What are the tools and competencies you need to appropriately manage patients with new or refractory IFIs?

- ☐ Knowledge of current guidelines
- ☐ Knowledge of the most common fungal pathogens in my region
- ☐ Knowledge of the latest clinical research with newer agents
- ☐ Strategies for selecting the most appropriate antifungal agent based on the pathogen
- ☐ Practical guide on the use of the latest diagnostic techniques
- ☐ Criteria that can be used for empiric antifungal selection
- ☐ Criteria on when susceptibility testing is needed
- ☐ Strategies to use when initial antifungal treatment fails
- ☐ Other (please specify) _____

CREDIT APPLICATION (Please Print)

Name and Degree _____

Address _____

City _____ State _____ ZIP _____

E-mail address _____ May we contact you by e-mail? ☐ Yes ☐ No

Type of credit requested ☐ ACPE ☐ AMA

I certify that I participated in *From Pre-Emptive to Salvage Antifungal Therapy: Achieving Successful Outcomes*.

Signature _____ **Date** _____

For questions regarding accreditation of this activity, please contact Center for Independent Healthcare Education at info@jointsponsor.com.